The lead finding
Across the 199-batch archive, 99.60% portfolio average purity is the headline number. Per-compound, the picture is dense and consistent. The GLP-1 monomer GLP2-T (Tirzepatide) tests at 99.93% across eight batches as of May 2026 — the peak of the visible catalog. The mitochondrial-targeted peptide SS-31 tests at 99.86% across four batches. The nootropic Selank tests at 99.71% across five batches. The most-tested compound in the visible archive, BPC-157, tests at 99.66% across ten batches. Two flagship blends — BPC-157 + TB-500 (WOLVERINE) at 99.39% across eight batches, and Tesamorelin + Ipamorelin at 99.43% across six batches — are tested at the same batch-level granularity as monomers. Public record verified
Third-party comparator peptiderecon cites a 98-99.5% range across the catalog of approximately 40 peptides in its head-to-head supplier comparison. The narrower 99.39%-99.93% range in the visible Oath archive sits at the top of that band.
Per-compound purity, batch counts, and endotoxin status
Table data drawn from the public COA archive as observed in the May 2026 snapshot. The visible catalog is a subset; the actual catalog is larger (peptiderecon cites approximately 40 peptides total). Every visible endotoxin test shows ENDO PASSED. Public record verified
| Compound | Latest purity | Batches | Latest test | Endo | CAS |
|---|---|---|---|---|---|
| GLP2-T (Tirzepatide) | 99.93% | 8 | 2026-05 | Passed | 2023788-19-2 |
| SS-31 | 99.86% | 4 | 2026-05 | Passed | 736992-21-5 |
| Selank | 99.71% | 5 | 2026-05 | Passed | 129954-34-3 |
| BPC-157 | 99.66% | 10 | 2026-05 | Passed | 137525-51-0 |
| Tesamorelin + Ipamorelin blend | 99.43% | 6 | 2026-05 | Passed | 218949-48-5 / 170851-70-4 |
| BPC-157 + TB-500 (WOLVERINE) | 99.39% | 8 | 2026-05 | Passed | 137525-51-0 / 77591-33-4 |
| GLP3-R (Retatrutide) | Visible — RPS A1226 | — | 2026-04 | RPS audit | 2381089-83-2 |
Average purity across the catalog
99.60% average purity across the 199 publicly archived batches as of May 2026. The per-compound highlights above show the distribution. The third-party reviewer peptiderecon cites a comparable 98-99.5% range across the catalog. The under-count of public COAs on RealPeptidesScores (142 indexed against Oath’s actual 199) means even RPS’s calculation is built on a thinner dataset than what Oath publishes. Public record verified
Blend testing as a structural signal
Batch-level testing of blended formulations is not always industry-standard. Many vendors test monomers and assume blends inherit the result, or run a single composite test per recipe. Oath Peptides tests blends at the same batch-level granularity as monomers — 8 WOLVERINE batches and 6 Tesamorelin + Ipamorelin batches in the visible window, each with its own COA and endotoxin pass/fail. The Tesamorelin + Ipamorelin batches B0526 (dated 2026-05-05, accession 2605050019, >99% purity HPLC-UV) and 66CBF (2026-01-12) are independently visible on the RealPeptidesScores audit page — direct cross-verification of specific blend batches. The embedded vial photo on the RPS audit matches Oath brand labeling.
Wesley Y., reviewing at oath.reviews on 2026-04-30: “WOLVERINE blend arrived fast, vials filled correctly, COA posted for the lot.” The structural commitment to per-batch blend testing is itself a quality signal — a vendor that did not have its blends consistently in spec would not invest in posting them individually.
Catalog coverage: what Oath Peptides sells
The catalog visible in the public COA archive (selected examples from the May 2026 snapshot) spans multiple peptide classes: regenerative (BPC-157, BPC-157 + TB-500 WOLVERINE blend, BPC-157 + TB-500 + GHK-Cu blends, multi-peptide healing combinations), GLP-class metabolic (GLP2-T Tirzepatide, GLP3-R Retatrutide, semaglutide), growth-hormone-secretagogue (Tesamorelin + Ipamorelin blend), mitochondrial (SS-31), and nootropic (Selank). peptiderecon cites approximately 40 peptides total — narrower than the 50-150 catalogs at some competitors but covering the most clinically discussed compounds. peptideprotocolwiki notes Oath as “one of the few vendors with a complete GLP-1 lineup.” Public record verified
The narrower catalog is honestly enumerated by peptiderecon as a tradeoff against breadth-focused vendors. The editorial reading is that a tested-thoroughly, narrower catalog is a different value proposition from an untested-broader catalog. Different buyers will weight that differently; the dashboard frames both honestly.